Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.
about
Aberrantly expressed microRNAs in the context of bladder tumorigenesisInhibiting Immune Checkpoints for the Treatment of Bladder Cancerdigit-a tool for detection and identification of genomic interchromosomal translocationsAge-related somatic mutations in the cancer genomeLong noncoding RNA GHET1 promotes the development of bladder cancerRecurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.Molecular biology of bladder cancer.Modelling bladder cancer in mice: opportunities and challenges.Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneityNucleolar GTP-binding Protein-1 (NGP-1) Promotes G1 to S Phase Transition by Activating Cyclin-dependent Kinase Inhibitor p21 Cip1/Waf1.Factors influencing success of clinical genome sequencing across a broad spectrum of disordersOncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer.The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer.Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours.Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Next-generation technologies for multiomics approaches including interactome sequencing.Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.Crowdsourcing for translational research: analysis of biomarker expression using cancer microarrays.Genomic Instability in Cancer: Teetering on the Limit of Tolerance.Characterization of potential driver mutations involved in human breast cancer by computational approaches.Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.Pan-cancer analysis of the extent and consequences of intratumor heterogeneity.Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance.In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.Variant Review with the Integrative Genomics Viewer.Network-Based Coverage of Mutational Profiles Reveals Cancer Genes.Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression.
P2860
Q26744152-068BA83E-4CFC-4A26-B433-AC71B5A92C80Q26744758-EBE3ADDD-465A-4653-BE16-C11DEC3A5C09Q33701551-1E9A6056-B3C5-4217-8EA4-A99E09F5E712Q34494738-AB44B0B1-E868-4CA9-B088-BD313A0FEDB4Q34501968-5747729F-0FC4-40E7-B070-7F1A692619E7Q35247152-C5974FEF-7EBD-423C-A7EA-7DC2B2A2A379Q35266400-F262D047-E4F0-4682-BE09-CD9D79717370Q35285703-643B9378-8390-4866-9064-FC23AE3649E9Q35891370-85F8EB0E-33B9-4029-B372-EB2B31E323FBQ36065105-24544E34-EC54-4BAD-B691-BC6B363C68F3Q36147983-7C66B657-337A-489E-A10D-8FE3E92A3716Q36269679-F39E4E8A-C9AB-4C06-B616-2ED1A4209D04Q36292777-107F109F-F695-42B8-B7A3-6E60C2B6C572Q36328938-9E83D3E9-51A0-4A95-86D3-9BA5DCED267FQ36771895-4600E1D0-F3F5-48D4-AC14-9F3170EEBF3BQ36862527-033AA397-3552-49EA-9CFF-144C9B3BC895Q36907205-2DE9F7C5-744A-49A5-821D-5C1A9AFF2D42Q37718224-CE2F0360-E781-4449-89F4-172F06B2D3D7Q38343369-A9555F2C-3671-497F-9CD5-BEF6F31815B1Q38796338-13EEEB2D-2AA2-4C29-8930-28131AE94D28Q39105241-22326673-78DA-43DB-B548-7071D335B13CQ39255507-3D7F7EFD-4045-4FB0-8854-0C82FBC90791Q39286993-CDD20F12-A4CA-432D-BF85-A10D75490914Q39352697-B8B34E11-141A-4DD2-B160-746DB2185EC9Q40139573-F34722D7-8C36-47ED-A60B-DB4F4E1892A5Q40275671-312F098B-0F3A-4B35-B131-2153408EBAF9Q42378498-D017F922-3BC5-43E8-A051-8670CF298ADAQ42550010-BDBCED8E-B697-40F1-A026-905B84A7F2D9Q46183708-C1882E6B-3635-436C-A993-903BB5AED8FCQ47731072-536A67ED-C7C1-44EC-8E1F-4C8284FA01D8Q49548074-9EA55D36-C400-4D52-9F6A-7A2C6A1057DB
P2860
Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Whole-genome sequencing of bla ...... ciations with mutation burden.
@ast
Whole-genome sequencing of bla ...... ciations with mutation burden.
@en
Whole-genome sequencing of bla ...... ciations with mutation burden.
@nl
type
label
Whole-genome sequencing of bla ...... ciations with mutation burden.
@ast
Whole-genome sequencing of bla ...... ciations with mutation burden.
@en
Whole-genome sequencing of bla ...... ciations with mutation burden.
@nl
prefLabel
Whole-genome sequencing of bla ...... ciations with mutation burden.
@ast
Whole-genome sequencing of bla ...... ciations with mutation burden.
@en
Whole-genome sequencing of bla ...... ciations with mutation burden.
@nl
P2093
P2860
P50
P356
P1476
Whole-genome sequencing of bla ...... ciations with mutation burden.
@en
P2093
A K Walker
B J Wright
C Kartsonaki
E E M Jaeger
I P M Tomlinson
J-B Cazier
P2860
P2888
P356
10.1038/NCOMMS4756
P407
P577
2014-04-29T00:00:00Z
P5875
P6179
1020385203